Cerus Corporation

About Cerus Corporation

Cerus Corporation is a Concord, California medical device company and global leader in pathogen inactivation technology for blood components. Their INTERCEPT Blood System uses amotosalen and UVA illumination to inactivate viruses, bacteria, parasites, and leukocytes in donated platelets, plasma, and cryoprecipitate before transfusion. Products include the INT100 and INT200 UVA illumination devices (capital equipment leased or sold to blood centers) and a complete line of single-use sterile processing kits for platelets and plasma. FDA-approved (PMA BP140143 for platelets, BP130076 for plasma). Also manufactures INTERCEPT Fibrinogen Complex (IFC) for treatment of fibrinogen deficiency and massive hemorrhage. Publicly traded on NASDAQ (CERS). 2025 product revenue $206M. Keywords: pathogen inactivation, blood safety, pathogen reduction, INTERCEPT Blood System, platelets, plasma, cryoprecipitate, blood processing, transfusion medicine, blood center, amotosalen, psoralen, illuminator, FDA PMA, medical device, blood component.

By the Numbers

3E tracks 1 phone, 1 email, 1 website for Cerus Corporation. Create a free account to unlock contact details.

Brands Carried (1)

Quick Facts

Related companies

Find suppliers like Cerus Corporation

3E indexes 105,000+ vetted parts suppliers — manufacturers, authorized distributors, brokers, and surplus dealers across electronic, industrial, mechanical, and hard-to-find components. Search by part number, brand, or company name. Every search runs AI deep research that keeps hunting for new sources after you close the tab.